Study Summary
This trial is comparing two different treatments for cancer. One treatment is standard radiotherapy followed by surgery. The other treatment is a new immunotherapy drug called pembrolizumab, given before and after radiotherapy and surgery.
- Soft Tissue Sarcoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: 5 years
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
2 Treatment Groups
Standard of Care
1 of 2
Treatment
1 of 2
Active Control
Experimental Treatment
126 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the cap on participants for this clinical experiment?
"To successfully carry out this medical trial, 126 eligible patients must be enlisted. Merck Sharp & Dohme LLC is running the study from various locations including The Ohio State University and Johns Hopkins University." - Anonymous Online Contributor
Are there still opportunities to enroll in this experiment?
"Affirmative. According to the information recorded on clinicaltrials.gov, this trial is actively seeking volunteers and has been since July 19th 2017. The latest update was made March 25th 2022 and 126 patients are needed from 12 sites in total." - Anonymous Online Contributor
In which localities is this experiment being administered?
"This medical study has 15 total sites, with The Ohio State University in Columbus, Johns Hopkins University in Baltimore, and Duke University in Durham being three among them." - Anonymous Online Contributor
What has been the primary application of Pembrolizumab?
"Pembrolizumab is frequently employed to treat cancerous neoplasms and has been used with some success in cases of unresectable melanoma, microsatellite instability high, or those who have experienced disease progression after chemotherapy." - Anonymous Online Contributor
To what extent do the risks of Pembrolizumab outweigh its potential benefits?
"Based on the existing data, there is an assessment that pembrolizumab's safety can be rated a 2. This rating reflects their being clinical evidence for its safety but not efficacy due to it only being in Phase 2 of trials." - Anonymous Online Contributor
Has Pembrolizumab been the subject of prior investigations?
"Pembrolizumab was initially researched at City of Hope in 2010, with 251 trials having been concluded since then. Currently, there are 961 active clinical studies being conducted across the US, many located in Columbus, Ohio." - Anonymous Online Contributor